We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+2.07%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$275M
AUM Growth
+$31.8M
Cap. Flow
+$49.2M
Cap. Flow %
17.9%
Top 10 Hldgs %
71.85%
Holding
21
New
2
Increased
8
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$26.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$13.3M
3
TYRA icon
Tyra Biosciences
TYRA
+$9.54M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$6.87M
5
VRNA
Verona Pharma
VRNA
+$4.9M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$8.57M
2
AXSM icon
Axsome Therapeutics
AXSM
+$4.87M
3
ARGX icon
argenx
ARGX
+$3.33M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$2.74M
5
ZGNX
Zogenix, Inc.
ZGNX
+$437K

Sector Composition

Rank Sector Weight
1 Healthcare 94.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$22.9B
$36.2M 13.16%
1,313,607
+29,720
+2% +$780K
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$29.5M 10.73%
1,942,259
-28,000
-1% -$437K
NUVL
3
DELISTED
Nuvalent
NUVL
$20.6M 7.5%
+914,614
New +$26.5M
ALLK
4
DELISTED
Allakos
ALLK
$18.6M 6.75%
175,362
+23,200
+15% +$2.07M
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$375M
$18M 6.55%
316,952
+138,894
+78% +$6.87M
ARGX icon
6
argenx
ARGX
$56.1B
$17.7M 6.44%
58,644
-10,500
-15% -$3.33M
TRIL
7
DELISTED
Trillium Therapeutics Inc.
TRIL
$15.6M 5.66%
886,281
-10,000
-1% -$117K
VRDN icon
8
Viridian Therapeutics
VRDN
$2.2B
$15.5M 5.65%
944,092
+909,000
+2,590% +$13.3M
COGT icon
9
Cogent Biosciences
COGT
$6.9B
$13.1M 4.77%
1,558,975
– –
AMRN
10
Amarin Corp
AMRN
$286M
$12.8M 4.65%
125,412
-1,250
-1% -$123K
TIL icon
11
Instil Bio
TIL
$48.4M
$12M 4.38%
33,695
– –
IOVA icon
12
Iovance Biotherapeutics
IOVA
$2.2B
$9.61M 3.49%
389,588
-116,302
-23% -$2.74M
TYRA icon
13
Tyra Biosciences
TYRA
$1.89B
$8.78M 3.19%
+499,040
New +$9.54M
PNT
14
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.46M 3.07%
1,099,489
+235,275
+27% +$2.15M
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$8.06M 2.93%
911,736
+229,708
+34% +$2.2M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.4B
$6.92M 2.52%
416,817
-7,000
-2% -$135K
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.37M 2.32%
250,000
+40,000
+19% +$1.18M
AXSM icon
18
Axsome Therapeutics
AXSM
$12.3B
$6.18M 2.25%
187,598
-125,000
-40% -$4.87M
KROS icon
19
Keros Therapeutics
KROS
$205M
$5.91M 2.15%
149,333
– –
VRNA
20
DELISTED
Verona Pharma
VRNA
$5.08M 1.85%
926,602
+842,658
+1,004% +$4.9M
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
– –
-888,980
Closed -$8.57M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q3 2021 Portfolio in Review

As of Q3 2021, Fairmount Funds Management held 21 positions worth $275M, up 13% from $243M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Fairmount Funds Management deployed $49.2M of net new capital in Q3 2021, opening 2 new positions and adding to 8 existing holdings. Its largest new stake was Nuvalent: 914,614 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.87M trimmed.

  • Fairmount Funds Management's largest Q3 2021 buy was Nuvalent: 914,614 shares worth $20.6M.
  • Fairmount Funds Management added most to Viridian Therapeutics in Q3 2021, an estimated $13.3M increase.
  • Fairmount Funds Management's biggest Q3 2021 reduction was Axsome Therapeutics, cutting an estimated $4.87M.
  • Fairmount Funds Management fully exited Amicus Therapeutics in Q3 2021, selling an estimated $8.57M.
  • Fairmount Funds Management's ten largest holdings make up 72% of its $275M portfolio in Q3 2021.
  • Fairmount Funds Management opened 2 new positions and closed 1 in Q3 2021.
  • Fairmount Funds Management's portfolio value rose 13% quarter-over-quarter to $275M.

Based on Fairmount Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.